• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·BSEM
Share

BioStem Technologies, Inc. Stocks

$ 1.57Last Updated 23.10.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 29.32M

$ 1.57
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

25.02.2025 16:59

Zacks recommends small-cap drugmaker BioStem that has sunk 30% in three weeks

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Very favourable
7/7
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.10.2026 02:47

Investors' appetite for risk has returned: AI sector stocks started the week on an upswing

27.10.2026 01:51

Anthropic reveals dependence on Google, Amazon, and Microsoft ahead of IPO

27.10.2026 00:38

Microsoft is cutting costs: 60,000 employees have been offered voluntary separation

27.10.2026 00:18

‘It’ll likely start as a credit event’: How neocloud woes threaten the S&P 500

26.10.2026 23:40

Buyers of the foldable iPhone have complained about screen damage. How does this affect the stock price?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026